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Introduction  and  objectives:  Over  the  last  decade,  several  studies  have  suggested  that  left
ventricular  endomyocardial  biopsy  is  safer  and  has  a  higher  diagnostic  yield  than  transvenous
right ventricular  biopsy.  In  addition,  recent  publications  indicate  that  the  transradial  approach  is
a feasible  and  safe  alternative  to  the  transfemoral  approach  for  sampling  the  left  ventricle.  We
report our  initial  experience  with  transradial  endomyocardial  biopsy  with  regards  to  feasibility,
safety and  usefulness.
Methods:  Single-center  registry  of  consecutive  patients  undergoing  intended  transradial  left
endomyocardial  biopsy.  Clinical  and  technical  data  were  collected  prospectively,  with  a  partic-
ular focus  on  success  rate  and  complications.
Results:  Twenty-seven  patients  were  screened  for  left  ventricle  biopsy.  Twenty  (25)  were
selected for  an  intended  transradial  approach  (mean  age  51±18  years  old,  22  male).  Success
rate was  100%  with  no  crossover  to  femoral  approach.  There  were  no  major  complications.  Two
patients experienced  mild  radial  spasm.  One  of  them  also  had  a  run  of  non-sustained  ventricular
tachycardia.Indication  for  biopsy  was  either  myocarditis  or  cardiomyopathy  of  unknown  etiology.  The
final diagnosis  was  acute  lymphocytic  myocarditis  in  five  patients,  chronic  myocarditis  in  one
patient, amyloid  light-chain  amyloidosis  in  four  patients  and  transthyretin  amyloidosis  in  six
patients. Myocarditis  was  ruled  out  in  eight  patients  and  amyloidosis  in  one  patient.∗ Corresponding author.
E-mail address: mnmenezes.gm@gmail.com (M. Nobre Menezes).
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Conclusions:  Transradial  left  ventricle  endomyocardial  biopsy  is  a  very  safe  and  feasible  method
of sampling  the  myocardium  for  histopathological  analysis,  with  a  good  diagnostic  yield  and
clinically  meaningful  results  in  properly  selected  patients.
© 2020  Sociedade  Portuguesa  de  Cardiologia.  Published  by  Elsevier  España,  S.L.U.  This  is  an









Exequibilidade,  segurança  e  utilidade  da  biópsia  endomiocárdica  ventricular
esquerda  por  acesso  transradial:  experiência  inicial  de  um  centro  universitário
terciário
Resumo
Introdução  e  objetivos:  Durante  a  última  década,  vários  estudos  têm  sugerido  que  a  biópsia
endomiocárdica  ventricular  esquerda  é  mais  segura  e  de  superior  rentabilidade  diagnóstica  do
que a  do  ventrículo  direito.  Adicionalmente,  várias  publicações  recentes  têm  introduzido  a
abordagem  transradial  como  uma  alternativa  exequível  e  segura  à  transfemoral,  para  amostrar
o ventrículo  esquerdo.  O  objetivo  deste  estudo  é  reportar  a  experiência  inicial  de  um  centro
em biópsia  endomiocárdica  ventricular  esquerda  transradial,  relativamente  a  exequibilidade,
segurança e  utilidade.
Métodos:  Registo  unicêntrico  de  doentes  consecutivos  submetidos  a  biópsia  endomiocárdica
ventricular  esquerda,  com  acesso  de  primeira  intenção  radial.  Registaram-se  os  dados  clínicos
e técnicos,  com  particular  foco  na  taxa  de  sucesso  e  complicações.
Resultados:  Foram  submetidos  a  biópsia  endomiocárdica  ventricular  esquerda  27  doentes,  25
dos quais  pré-selecionados  para  acesso  transradial  (idade  média  51±18,  22  homens).  A  taxa
de sucesso  foi  de  100%.  Não  ocorreram  complicações  major,  apenas  espasmo  radial  em  dois
doentes, num  dos  quais  se  observou  uma  salva  de  taquicardia  ventricular  não  mantida.  A
indicação foi  miocardite  ou  miocardiopatia  de  etiologia  a  esclarecer.  O  diagnóstico  final  foi
de miocardite  aguda  em  cinco  doentes,  miocardite  crónica  em  um  doente,  amiloidose  AL  em
quatro doentes  e  ATTR  em  seis  doentes.  Excluiu-se  miocardite  em  oito  doentes  e  amiloidose
em um  doente.
Conclusão:  A  biópsia  endomiocárdica  ventricular  esquerda  transradial  demonstrou  ser  segura,
exequível e  de  boa  rentabilidade  diagnóstica,  com  resultados  clinicamente  relevantes  em
doentes selecionados.
©  2020  Sociedade  Portuguesa  de  Cardiologia.  Publicado  por  Elsevier  España,  S.L.U.  Este é um
































he  development  of  endomyocardial  biopsy  in  the  1960s
acilitated  percutaneous  sampling  of  the  myocardium  with-
ut  the  need  for  a  grossly  invasive  procedure.1 However,
n  recent  decades,  significant  advances  in  both  invasive
nd  non-invasive  cardiac  imaging  have  enabled  the  study
f  a  wide  array  of  cardiac  diseases,  without  the  need
or  a  histopathological  analysis  of  the  heart.  As  a  result,
nthusiasm  for  myocardial  biopsy  has  waned.  Indeed,  the
ost  recent  recommendations  regarding  endomyocardial
iopsy  date  back  to  2007,  and  a  high  level  of  recommen-
ation  applies  in  only  a  handful  of  settings.2 However,
hese  guidelines  base  their  recommendations  on  efficacy
nd  safety  data  in  existence  at  that  time.  Since  then,
wo  main  changes  have  occurred:  Firstly,  several  authors
ave  published  extensive  data  on  an  approach  via  the  left
entricle  rather  than  just  the  right  ventricle,  allowing  for




perators  started  performing  left  ventricular  (LV)  biopsy
sing  the  radial  approach,  widely  popular  in  the  interven-
ional  community  for  its  simplicity,  comfort  and  increased
afety.5 As  a  result,  more  recent  documents  call  for  a
ider  use  of  this  technique,  particularly  in  myocarditis,6,7
ilated  cardiomyopathy8 and  myocardial  infarction  with
on-obstructive  coronary  artery  disease.9
In  this  paper,  we  report  our  initial  experience  of  the  fea-
ibility,  safety  and  usefulness  of  transradial  endomyocardial
iopsy.
ethods
eneral  featureshis  study  involved  a  single-center  registry  of  consecutive
atients  undergoing  intended  transradial  endomyocardial
iopsy.  Patients  were  selected  for  endomyocardial  biopsy  of
y  455
Figure  1  Contrast  injection  into  the  left  ventricle  after  guide
catheter  placement.
Figure  2  Bioptome  deployment  with  open  forceps,  immedi-







Transradial  left  ventricular  endomyocardial  biopsy  feasibilit
the  left  ventricle  and  screened  for  the  feasibility  of  radial
access  individually,  based  on  the  operator’s  clinical  judg-
ment.
Clinical  data  included  demographics,  clinical  setting,
imaging,  complications,  and  final  biopsy  results.  Technical
data  included  access  site,  sheath/catheter  size  and  shape,
biopsy  model  and  size,  procedural  time,  fluoroscopy  time,
success  rate  and  cross-over  rate  to  femoral  approach.
Statistical  analysis
This  is  a  descriptive  registry;  complex  statistical  analysis
was  not  performed.  Qualitative  variables  are  expressed  both
numerically  and  in  percentages.  Continuous  variables  are
depicted  as  mean  ±  standard  deviation  and  range,  where
appropriate.  SPSS  Statistics  24  was  used  for  analysis.
Procedure  overview
Detailed  information  on  technique  has  been  published  in
recent  papers.10--13 However,  because  minor  variation  occurs
across  centers  and  operators,  an  overview  of  the  technique
as  it  was  performed  is  provided.
The  procedure  was  always  undertaken  by  the  same
operator,  who  had  been  previously  trained  in  transradial
intervention  and  in  performing  left  myocardial  biopsies.  Dur-
ing  the  procedure,  the  patient  was  continuously  monitored
as  in  a  routine  coronary  angiography  (i.e.  with  continuous
12-lead  electrocardiogram  and  invasive  blood  pressure  mea-
surement).
Routine  transthoracic  echocardiography  was  performed
before,  during  and  after  the  procedure.  Particular  atten-
tion  was  given  to  documenting  and  quantifying  pericardial
effusion  and  mitral  regurgitation,  as  well  as  excluding  the
presence  of  LV  thrombus  or  masses  which  might  contraindi-
cate  the  procedure.
Spasm  prophylaxis  with  intra-arterial  0.5-1  mg  of  isosor-
bide  dinitrate  and/or  2.5  mg  of  verapamil  and  5000  units  of
unfractionated  heparin  were  administered.
If  the  patient  required  a  coronary  angiogram,  a  stan-
dard  transradial  coronary  angiogram  was  performed  using
a  Terumo  5/6  Fr  slender  sheath  (external  diameter  5  Fr)  and
standard  Judkins  5  Fr  coronary  diagnostic  catheters.
Afterwards,  a  7.5  Fr  (external  diameter  6  Fr)  Asahi
Eaucath  sheathless  guide  catheter  was  advanced  over  a  stan-
dard  0.035’’  J  wire  to  the  ascending  aorta.  An  MP  1  or  JR
3.5/4  curve  was  used  according  to  operator  choice.  The
dilator  was  removed  and  a  5  Fr  pigtail  catheter  was  then
used  inside  the  7.5  Fr  for  crossing  the  aortic  valve  and
safely’’landing’’  in  the  left  ventricle.  The  guide  catheter
was  advanced  over  the  pigtail,  which  was  then  removed,  and
placed  in  the  mid-cavity  of  the  left  ventricle.  The  catheter
was  connected  to  the  pressure  system,  initial  LV  pressure
was  recorded  and  a  minimal  amount  of  contrast  was  injected
(Figure  1).  A  5.5  Fr  Cordis  104  cm  or  5.4  Fr  Maslanka  120
cm  bioptome  was  advanced  and  the  myocardial  wall  was
sampled  (Figure  2).  Back-bleed  from  the  catheter  and,  if
necessary,  aspiration,  were  then  performed  to  ensure  no
air  bubbles  were  in  the  system.  These  steps  were  then




as  obtained  --  a  minimum  of  five  --  of  which  at  least  one
as  frozen  for  further  analysis,  if  necessary.
All  mid-apical  segments  of  all  the  walls  of  the  left  ven-
ricle  were  sampled  by  gently  directing  the  catheter  during
he  procedure,  guided  by  fluoroscopy  and  echocardiogra-
hy.  First  the  guide  is  positioned  using  fluoroscopy  and  then
onfirmed  by  transthoracic  echocardiography  by  an  assisting
hysician.  This  enables  detailed  guide  and  bioptome  posi-
ioning  and  early  identification  of  possible  complications.
he  process  was  repeated  for  all  samples.
Hemostasis  was  obtained  using  the  Terumo  TR-Band.
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Table  1  Baseline  clinical  characteristics.
Characteristic  N(%)  or  mean  ±
standard  deviation
Age  51±18
Male  22  (88%)
Hypertension  13  (52%)
Dyslipidemia  9  (36%)
Diabetes  mellitus  2  (8%)
Smoking  habits  7  (28%)
Chronic  kidney  disease
(CrCl<60)
5  (20%)
Heart  failure 13  (52%)
NYHA  I 0
NYHA  II  9  (36%)
NYHA  III  4  (16%)
NYHA  IV  0
Reduced  EF  (<52%  male,  <54%
female)
11  (44%)
Previous  CAD  0
Newly  diagnosed  CAD  0
Baseline  rhythm
Sinus  22  (88%)
Temporary  pacing  1  (4%)
Permanent  pacing  2  (8%)
Inpatient  procedures  13  (52%)
Elective  procedures  12  (48%)
Previous  RV  biopsy/Previous
LV  biopsy
1  (5%)/0  (0%)





















Table  2  Technical  data,  success  and  complications.
Parameter  N(%)  or  mean  ±
standard  deviation
Success  25  (100%)
Cross-over  to  femoral  0  (0%)
Major  complications  0  (0%)
Perforation  0  (0%)
Cardiac  tamponade  0  (0%)
De novo  or  increased  mitral
regurgitation
0  (0%)
Embolization  0  (0%)
Permanent  AV  block 0  (0%)
Tachycardia  requiring  termination  by
cardioversion
0  (0%)
Minor  complications  2  (8%)*
Arrhythmias  1  (4%)
Sinus  bradycardia  0  (0%)
Transient  AV  block  0  (0%)
Other  conduction  disturbance  0  (0%)




Sustained  ventricular  tachycardia  0  (0%)
Radial  spasm  2  (8%)**
Bleeding  0  (0%)
Access  site  hematoma  0  (0%)
Pseudoaneurysm  or  aneurysm
formation
0  (0%)
Right  radial  /  Left  radial 23  (92%)/2  (8%)
Concomitant  coronary  angiography  20  (80%)
Guide  Catheter
MP  1  19  (76%)
JR 3.5/4  6  (24%)
Bioptome
Cordis  5.5  Fr  104  cm  19  (76%)
Maslanka  5.4  Fr  120  cm  6  (24%)
Procedural  time*** 35±8
Fluroscopy  time*** 9±2
Number  of  myocardium  samples
Mean±SD  7±1
Range  5-10
AV: atrioventricular; MP: Multipurpose; JR: Judkins Right.








ejection fraction; LV: left ventricular; NYHA: New York Heart
Association; RV: right ventricular.
esults
aseline  population  characteristics
wenty-five  patients  were  selected  for  intended  LV  endomy-
cardial  biopsy.  Two  patients  underwent  the  procedure  in
he  setting  of  cardiogenic  shock  of  unknown  etiology  and
ere  deemed  better  suited  to  a  transfemoral  approach,
s  mechanical  circulatory  support  was  being  considered
ost  procedure.  Transradial  endomyocardial  biopsy  was  thus
ttempted  in  25  patients.  The  baseline  data  are  illustrated
n  Table  1.
echnical  data,  success  and  complications
ll  patients  scheduled  for  transradial  biopsy  underwent  the
rocedure  successfully,  with  no  cases  of  cross-over  to  a
emoral  approach.  There  were  no  major  complications,  and
nly  two  cases  of  minor  radial  spasm.  One  of  these  two
atients  also  had  a  run  of  non-sustained  ventricular  tachy-
ardia  (Table  2).
Regarding  the  two  above-mentioned  patients  who  under-
ent  programmed  transfemoral  LV  endomyocardial  biopsy,




** Mild radial spasm.
*** Including coronary angiography when performed.
iopsy  indication,  results  and  final  clinical
iagnosis
here  were  two  main  clinical  settings  for  performing  the
rocedure:  myocarditis  and  cardiomyopathy.  The  details  are
rovided  in  Table  3.
Regarding  myocarditis,  eight  studies  were  performed  in
he  setting  of  suspected  acute  myocarditis  (Figure  3A  and
B).Three  patients  presented  with  acute  coronary  syndrome
hest  pain-like  symptoms.  Two  of  them  underwent  the  pro-
edure  because  of  recurrent  myocarditis.  The  third  patient
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Table  3  Indication  for  biopsy  and  final  result.
Indication  --  N(%)  Final  Result
Acute  myocarditis  (clinically  suspected  myocarditis)  8  (32%)  5  confirmed
3 ruled  out
New-onset HF  4  (16%)  2  confirmed
2 ruled  out
3rd degree  AV  block  1  (4%)  1  Ruled  out
No signs  of  HF  or  serious  arrythmias  3  (12%)  3  confirmed
Chronic myocarditis
(clinically  suspected  -  DCM  with  HF)
6  (24%)  1  confirmed
5 ruled  out
Hypertrophic cardiomyopathy 11  (44%)
AHCM with  clinical  features  of  amyloidosis 2  (8%) 2  ATTR  amyloidosis
Suspected  cardiac  amyloidosis  with  previous
inconclusive  studies
9  (36%) 4  AL  amyloidosis
4  ATTR  amyloidosis
1 ruled  out
AHCM: apical hypertrophic cardiomyopathy; ATTR: transthyretin; AL: amyloid light-chain; AV: atrioventricular; DCM: dilated cardiomy-
opathy; HF: heart failure.





















wild  type  ATTR  amyloidosis  in  four  patients.  One  patientAbsence of  fibrosis  (hematoxylin  and  eosin).  (B)  Interstitial  lym
are present  (hematoxylin  and  eosin).
underwent  the  procedure  due  to  very  high  troponin  levels
and  mildly  impaired  LV  function,  despite  the  absence  of
clinical  signs  of  heart  failure.  All  had  a  favorable  clinical  out-
come  with  normalization  of  LV  function  after  a  few  weeks.
Their  final  diagnosis  was  acute  lymphocytic  myocarditis.  One
patient  had  a  mildly  positive  parvovirus  B19  result  in  the
polymerase  chain  reaction  (PCR)  test.
Four  patients  underwent  the  procedure  because  of  new-
onset  heart  failure  of  unknown  etiology.  They  had  no
other  characteristics  of  acute  myocarditis  but  a  poten-
tially  treatable  type  of  myocarditis,  such  as  giant  cell
myocarditis,  was  ruled  out,  thereby  excluding  an  indica-
tion  for  immunosuppression  therapy.  Two  of  these  patients
tested  positive  for  acute  lymphocytic  myocarditis,  one  in
the  setting  of  Takayasu  arteritis,  and  progressed  favor-
ably,  with  normalization  of  LV  function  after  a  few
weeks.
One  patient  was  a  46-year-old  patient  with  new-onset
third  degree  atrioventricular  (AV)  block.  The  biopsy  ruled
out  myocarditis,  but  showed  some  degree  of  fibrosis,  possi-
bly  related  to  past  radiotherapy  years  earlier  in  the  setting
of  Hodgkin’s  lymphoma.  The  result  helped  to  explain  the
etiology  of  the  AV  block  at  such  a  young  age  and  reinforced
the  need  for  a  permanent  pacemaker,  as  the  cause  of  the




ytic  infiltration  and  myocyte  damage  in  the  form  of  apoptosis
Six  patients  underwent  the  procedure  in  the  setting  of
ilated  cardiomyopathy  for  ruling  out  chronic  myocarditis.
hey  were  young  patients  (age  range  23-56  years)  refractory
o  medical  therapy  for  heart  failure  titrated  to  maximum
oses.  Only  one  met  the  formal  pathological  criteria  of
hronic  myocarditis.6 The  study  of  viral  genomes  by  PCR  was
egative.
Regarding  those  patients  who  underwent  the  procedure
n  the  setting  of  cardiomyopathy,  there  were  two  cases
f  apical  hypertrophy  with  imaging  and  clinical  features
f  concomitant  amyloidosis.  Therefore,  the  exact  etiology
f  their  cardiomyopathy  was  not  fully  understood.  Their
nal  diagnosis  was  familial  transthyretin  (ATTR)  amyloidosis
V30M  mutation)  cardiomyopathy.  Nine  patients  under-
ent  endomyocardial  biopsy  due  to  amyloidosis  (Figure  4A,
nd  4C)  of  unknown  etiology  after  earlier  studies,  which
ncluded  laboratory  workup  and  an  abdominal  fat  biopsy.
he  echocardiograms  of  eight  patients  were  highly  sug-
estive  of  amyloidosis.  The  final  diagnosis  was  amyloid
ight-chain  amyloidosis  in  four  cases  (resulting  in  hematol-
gy  referral  for  the  study  of  lymphoproliferative  diseases),as  referred  by  another  institution  to  the  amyloidosis  clinic
ecause  of  an  inconclusive  echocardiogram  together  with
 cardiac  magnetic  resonance  raising  the  possibility  of
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Figure  4  (A)  Light-chain  cardiac  amyloidosis.  Hyalin  widening
of the  interstitial  space  in  the  myocardial  tissue  (hema-
toxylin and  eosin).  (B)  Extracellular  amyloid  deposits  in  the
endocardium  and  surrounding  the  cardiomyocytes  (Congo  red
































































ellular  amyloid  deposits  (immunohistochemical  method  with
n anti-lambda  light-chain  antibody).
myloidosis,  which  was  ruled  out  in  the  cardiac  biopsy.  It  is
oteworthy  that  all  six  patients  with  ATTR  amyloid  deposits
ad  their  TTR  gene  sequenced.
Finally,  the  two  previously  mentioned  patients,  who
nderwent  the  transfemoral  procedure,  were  also  new-
nset  heart  failure  cases  with  cardiogenic  shock  after
ardiac  arrest;  myocarditis  was  ruled  out  in  both.iscussion
n  our  initial  experience,  transradial  endomyocardial  biopsy
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uccess  and  complications.  Our  research  is  supported  by
n  increasing  amount  of  published  data  on  this  particular
pproach  to  endomyocardial  biopsy.
Safety  is  the  major  concern  when  performing  this  tech-
ique,  as  many  patients  are  often  young  (especially  in  the
etting  of  myocarditis)  and  others  have  large  ventricles
ith  thin  walls.  We  did  not  encounter  safety  issues,  espe-
ially  perforation,  embolization  or  mitral  regurgitation.  This
as  likely  the  result  of  specific  operator  training  both  in
adial  intervention  and  LV  biopsy,  as  well  as  technical  safety
recautions.  We  highlight  the  use  of  pressure  monitoring,
xtensive  back  bleed  and  catheter  aspiration,  as  well  as
eri  and  intra-procedural  echocardiography  guidance.  All
f  these  enable  constant  monitoring  of  the  procedure  and
inimize  risks.
As  mentioned  above,  current  guidelines  regarding
ndomyocardial  biopsy  are  now  over  a  decade  old  and  base
heir  safety  considerations  on  even  older  data.2 Indeed,
hese  recommendations  highlight  a large  series  of  transve-
ous  RV  biopsies  with  an  overall  6%  complication  rate,  a  1.2%
ossible  or  definite  perforation  rate  and  0.4%  death  rate.14
ver  the  past  decade,  however,  several  authors  from  expe-
ienced  European  centers  have  published  more  extensive
xperience  (ranging  from  755  to  4221  procedures)  totaling
ore  than  8000  procedures.3,4,15 In  addition,  two  of  these
ublications  provide  extensive  data  on  both  left  and  RV
iopsy,  thereby  providing  clearer  data.3,4 Overall,  the  pub-
ished  major  and  minor  complication  rate  of  these  authors
anges  from  0.12%  to  0.82%  and  1.35  to  5.2%,  respectively,
egarding  RV  biopsies.3,4,15 The  rate  of  LV  biopsy  major  and
inor  complications  in  LV  biopsies  was  0.33  to  0.64%  and
.2%  to  2.89%,  respectively.3,4 Importantly,  there  were  no
eaths  in  any  of  these  series.  Most  major  complications  were
erforation  with  subsequent  tamponade.  A  very  small  num-
er  were  cases  of  embolization.  Several  minor  complications
ncluded  bleeding  or  vascular-related.
These  data  provide  valuable  insights  into  safety.  Firstly,
he  risk  of  the  procedure  when  performed  in  experienced
enters  is  low,  and  seemingly  lower  than  previously  pub-
ished  studies;  secondly,  LV  biopsy  seems  at  least  as  safe,  if
ot  safer,  than  RV  biopsy.
Published  transradial  endomyocardial  biopsy  experience
s  quite  recent.  The  earliest  publications  date  back  to  201412
nd  2015.10,11 The  largest  series  published  to  date  was  mul-
icenter  data  comprising  over  100  patients.13 In  all  of  these
ecent  case  series,  there  were  no  major  complications.
urthermore,  the  latter  group  published  the  largest  radial
ersus  femoral  case  series  comparing  both  approaches,  with
29  cases  via  radial  and  134  cases  via  femoral  access.  There
ere  no  major  complications  and  bleeding  occurred  exclu-
ively  in  the  transfemoral  group.16
Our  experience  thus  reflects  the  findings  in  contempo-
ary  data.  Endomyocardial  biopsy  is  a  largely  safe  technique,
ll  the  more  so  when  performed  via  the  left  ventricle,
specially  with  the  added  safety  benefits  of  the  transradial
pproach.
In the  series  presented  herein,  the  feasibility  rate  was
00%,  with  no  cross-overs  and  only  mild  radial  spasm
bserved  in  two  patients.  This  was  likely  the  result  of  patient
election,  spasm  prophylaxis  administration,  the  use  of
ydrophilic  catheters  and  the  use  of  large  size  intra-luminal























invasive management: a randomised multicentre trial. Lancet
(London, England). 2015;385:2465--76.Transradial  left  ventricular  endomyocardial  biopsy  feasibilit
passage  and  have  a  reduced  external  caliper.  Importantly,
patient  feedback  was  very  positive  and  one  patient,  who  had
previously  undergone  a  transjugular  RV  biopsy  at  another
institution,  actively  voiced  his  preference  for  the  transra-
dial  technique,  because  of  improved  comfort.  When  the
procedure  is  performed  electively,  and  if  no  complications
occur,  same-day  discharge  is  possible.  Our  results  are  simi-
lar  to  previously  published  data.  In  fact,  in  the  largest  series
published  to  date,  cross-over  to  the  femoral  technique  was
required  in  only  one  patient  (0.98%).13
The  last  issue  regarding  this  technique  is  its  diagnostic
yield  and  clinical  usefulness.  In  our  experience,  in  which  LV
biopsy  was  always  performed  outside  the  setting  of  trans-
plant,  the  results  were  clinically  meaningful,  as  they  added
to  the  clinical  question  at  hand.  Indeed,  the  suspected  diag-
nosis  was  either  confirmed  or  ruled  out,  such  as  in  the
setting  of  myocarditis.  Additionally,  a  doubtful  diagnosis
was  clarified,  such  as  the  etiology  of  a  cardiomyopathy,  or
amyloidosis  infiltration  and/or  type  in  cases  with  predomi-
nant  heart  involvement  and  previously  inconclusive  studies.
Finally,  atypical  forms  of  LV  hypertrophy  (i.e.  apical)  were
observed  in  patients  with  ATTR,  and  tissue  biopsy  was  most
useful  for  confirming  amyloidosis  and  ruling  out  hypertrophy.
Importantly,  our  pathologist’s  feedback  was  also  very  pos-
itive,  as  the  quality  and  size  of  the  samples  was  deemed
excellent  and  better  than  when  we  had  previously  used  the
RV  approach.
The  abovementioned  papers  from  the  transfemoral  era
suggest  that  the  LV  approach  is  superior  to  the  RV  approach
outside  the  transplant  setting.  Indeed,  in  the  setting  of
myocarditis,  the  largest  published  series  reports  a  92.1%
vs.  81.3%  diagnostic  yield,4 and  in  the  setting  of  predom-
inant  LV  disease,  the  difference  is  quite  large  and  the  LV
approach  is  favored  with  97.8%  vs.  53%,  respectively.3 Pub-
lished  data  from  the  transradial  approach  do  not  allow  for
a  comparison  of  left  versus  right  approaches,  however  the
conclusions  are  similar  to  ours:  the  results  added  to  the  clini-
cal  dilemma,  confirming,  excluding  or  clarifying  a  diagnostic
hypothesis.13
Despite  its  advantages,  the  transradial  LV  endomy-
ocardial  biopsy  technique  is  not  without  limitations.  This
approach  requires  the  use  of  heparin,  which  may  add  to
the  risk  of  bleeding.  In  cases  in  which  repeated  biopsy  is
required,  such  as  transplant  patients,  radial  patency  and
the  risk  of  vascular  complications  may  become  an  issue
with  frequent  procedures.  In  addition,  the  LV  approach,
while  apparently  less  prone  to  perforation,  regardless  of
the  access  site,  may  lead  to  a  more  dangerous  scenario
should  perforation  occur,  given  the  much  higher  intra-
cavitary  pressure  of  the  left  ventricle.  Also,  the  risk
of  cerebral  embolization  is  essentially  a  concern  of  the
left,  rather  than  the  right,  approach,  and  thus  it  can-
not  be  performed  in  the  presence  of  LV  intracavitary
masses.
It  is  also  important  to  point  out  the  particular  limita-
tions  of  this  paper.  This  an  observational  single-center  study.
Additionally,  the  sample  size  is  relatively  small  given  the
single-center  nature  of  the  data.  And  finally,  an  ultrasound
study  of  the  radial  artery  was  not  performed  after  the  pro-
cedure.  Thus,  although  there  was  no  clinical  evidence  of
radial  patency  complications,  these  cannot  be  completely
ruled  out.459
onclusion
ransradial  LV  endomyocardial  biopsy  provides  a  safe  and
easible  method  of  sampling  the  myocardium  for  histopatho-
ogical  analysis,  with  a  good  diagnostic  yield  and  clinically
eaningful  results  in  properly  selected  patients.  This
echnique  should  probably  be  the  default  method  for
ndomyocardial  biopsy  in  patients  undergoing  a  single  biopsy
rocedure  outside  the  setting  of  cardiac  transplant  in  a
adial  center.
eypoints
 What  is  known  about  the  topic?
 The  indications  for  endomyocardial  biopsy  are  still
debated,  partly  because  of  safety  concerns  and  doubts
about  the  clinical  usefulness  of  the  results;
 Recent  papers  suggest  the  safety  of  LV  biopsy  is  superior
to  RV  biopsy;
 Very  recent  data  suggest  that  the  transradial  approach  is
a  new  and  better  method  of  sampling  the  left  ventricle
when  compared  to  the  transfemoral  approach.
 What  does  this  study  add?
 Additional  data  confirming  that  transradial  LV  biopsy  is
feasible  and  safe;
 Clinical  data  explaining  how  the  results  were  useful  in  a
variety  of  clinical  scenarios;
 Data  to  support  the  growing  indications  for  endomyocar-
dial  biopsy.
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